Stockreport

Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF 11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company's shares. The firm hig [Read more]